Cell rep:致病性 Th17 细胞调控新机制

2018-05-25 清华免疫 细胞

2018 年 5 月 22 日,清华大学免疫学研究所董晨课题组在《Cell Reports》在线发表题为 “Regulation of pathogenic T helper 17 cell differentiation by steroid receptor coactivator-3”的研究论文。该论文揭示了 SRC3 在致病性 Th17 细胞发育中的重要作用及其调控机制,为 Th17 细胞

2018 年 5 月 22 日,清华大学免疫学研究所董晨课题组在《Cell Reports》在线发表题为 “Regulation of pathogenic T helper 17 cell differentiation by steroid receptor coactivator-3”的研究论文。该论文揭示了 SRC3 在致病性 Th17 细胞发育中的重要作用及其调控机制,为 Th17 细胞相关疾病的治疗提供了新思路。


SRC3调控致病性Th17细胞发育机制

Th17 细胞由董晨课题组等发现,与多种自身性免疫疾病密切相关,并在不同环境和疾病中发挥保护性或致病性等不同功能。其早期发育受多种细胞因子和转录因子的调控,RORγt 为关键的调控 Th17 细胞发育的谱系特异性转录因子。目前,尽管有一系列研究阐述 Th17 细胞发育调控机制,但 Th17 细胞的不同功能如何被调控、RORγt 具体如何发挥作用仍不十分清楚。

Steroid-receptor coactivator-3 (SRC3) 是一种核受体共激活蛋白,与核受体 RID 区域和组蛋白乙酰酶 p300 结合促进靶基因转录。在本研究中,董晨课题组发现 T 细胞中 SRC3 的条件性敲除,能特异性抑制 IL-1/IL-6/IL-23 诱导的致病性 Th17 细胞的发育,影响 IL17a、IL17f、IL23r、IL22 等 Th17 细胞特异性基因的表达,而不影响其他辅助性 T 细胞、调节性 T 细胞和非致病性 Th17 细胞的发育。同时,SRC3 缺失能降低 Th17 细胞致病性,显着降低 EAE 模型的发病率并缓解发病进程及严重程度。

利用高通量测序技术,进一步研究发现,Il1r1 是 SRC3 的重要调控靶点,在 SRC3 缺陷 T 细胞中过表达 Il1r1 能有效地重新促进 Th17 细胞的发育并恢复在 EAE 模型中的致病性功能。一方面,SRC3 能直接与 RORγt 结合,进一步被招募到 IL17a 和 IL1r1 等区域促进其转录;另一方面,SRC3 缺陷能通过影响组蛋白甲基化和乙酰化修饰影响转录活性,并减少组蛋白乙酰化酶的结合。

董晨教授为该研究的通讯作者,董晨实验室以前的博士后 Kentaro Tanaka 和学生 Gustavo J. Martinez 是该文的共同第一作者,其合作者来自美国西雅图系统生物学研究所,休士顿贝勒医学院以及清华大学等。

原始出处:
Tanaka K, Martinez GJ, Yan X, et al.Regulation of Pathogenic T Helper 17 Cell Differentiation by Steroid Receptor Coactivator-3.Cell Rep. 2018 May 22;23(8):2318-2329. doi: 10.1016/j.celrep.2018.04.088.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1870661, encodeId=cfea18e0661ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 31 18:46:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718837, encodeId=0d741e18837b6, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Fri Oct 12 00:46:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960930, encodeId=c4a3196093095, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Nov 28 15:46:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413557, encodeId=a768141355eb8, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 27 05:46:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318608, encodeId=cde931860884, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat May 26 06:45:21 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318525, encodeId=cac0318525e8, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri May 25 20:19:49 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1870661, encodeId=cfea18e0661ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 31 18:46:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718837, encodeId=0d741e18837b6, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Fri Oct 12 00:46:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960930, encodeId=c4a3196093095, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Nov 28 15:46:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413557, encodeId=a768141355eb8, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 27 05:46:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318608, encodeId=cde931860884, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat May 26 06:45:21 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318525, encodeId=cac0318525e8, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri May 25 20:19:49 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
    2018-10-12 cnxcy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1870661, encodeId=cfea18e0661ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 31 18:46:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718837, encodeId=0d741e18837b6, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Fri Oct 12 00:46:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960930, encodeId=c4a3196093095, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Nov 28 15:46:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413557, encodeId=a768141355eb8, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 27 05:46:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318608, encodeId=cde931860884, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat May 26 06:45:21 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318525, encodeId=cac0318525e8, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri May 25 20:19:49 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
    2018-11-28 hb2008ye
  4. [GetPortalCommentsPageByObjectIdResponse(id=1870661, encodeId=cfea18e0661ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 31 18:46:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718837, encodeId=0d741e18837b6, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Fri Oct 12 00:46:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960930, encodeId=c4a3196093095, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Nov 28 15:46:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413557, encodeId=a768141355eb8, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 27 05:46:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318608, encodeId=cde931860884, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat May 26 06:45:21 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318525, encodeId=cac0318525e8, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri May 25 20:19:49 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
    2018-05-27 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1870661, encodeId=cfea18e0661ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 31 18:46:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718837, encodeId=0d741e18837b6, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Fri Oct 12 00:46:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960930, encodeId=c4a3196093095, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Nov 28 15:46:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413557, encodeId=a768141355eb8, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 27 05:46:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318608, encodeId=cde931860884, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat May 26 06:45:21 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318525, encodeId=cac0318525e8, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri May 25 20:19:49 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
    2018-05-26 kafei

    学习了谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1870661, encodeId=cfea18e0661ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 31 18:46:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718837, encodeId=0d741e18837b6, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Fri Oct 12 00:46:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960930, encodeId=c4a3196093095, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Nov 28 15:46:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413557, encodeId=a768141355eb8, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 27 05:46:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318608, encodeId=cde931860884, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat May 26 06:45:21 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318525, encodeId=cac0318525e8, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri May 25 20:19:49 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
    2018-05-25 131****1460

    学习了受益匪浅

    0

相关资讯

清华大学成立中药、监管科学两大研究院

4月10日,由清华大学药学院主办的“新时代中药传承与创新、药物创新与监管科学研讨会”在清华大学顺利召开。研讨会同时宣布成立清华大学“中药研究院”和“药品监管科学研究院”并举行揭牌仪式。两大研究院的创立旨在发挥自身优势推进中药现代化研究和监管科学两大领域发展,推动行业创新与升级

清华大学成立中药研究院:多学科交叉助推中医药传承创新

“中医药传承创新不只是中医药工作者的事,应该鼓励多学科交叉融合,打破界限,欢迎其他领域科研队伍加入。”4月10日,中国科学院院士陈凯先在由清华大学药学院主办的新时代中药传承与创新研讨会上说。清华大学中药研究院今日成立。

Nat Commun:再来1篇!清华大学董晨课题组报道Th17细胞发育调控新机制

2018年4月12日,清华大学免疫学研究所董晨课题组在《Nature Communications》在线发表题为“Epigenetic activation during T helper 17 cell differentiation is mediated by Tripartite motif containing 28” 的研究论文。该论文揭示了TRIM28在Th17细胞发育过程中的重要作

青年女科学家颜宁获“影响世界华人大奖”提名


颜宁于1977年11月出生于山东莱芜,2011年8月获得国家杰出青年科学基金资助,2012年获霍华德?休斯医学研究所国际青年科学家奖,2012年12月获中国青年女科学家奖 ,2014年12月入选教育部“***奖励计划”特聘教授 ,2015年2月获国际蛋白质学会“青年科学家奖” ,2015年10月获赛克勒国际生物物理奖。

2016年6月,因观察到了蛋白质在原子层面如何工作,并对细胞膜上嵌入蛋白质的结构展开了深入研究,颜宁入选《自然》杂志评选的“中国科学之星”之一。

高产的清华女

Cell Rep:又1篇!清华大学董晨团队报道致病性Th17细胞调控新机制

2018年5月22日,清华大学免疫学研究所董晨课题组在《Cell Reports》在线发表题为 “Regulation of pathogenic T helper 17 cell differentiation by steroid receptor coactivator-3”的研究论文。该论文揭示了SRC3在致病性Th17细胞发育中的重要作用及其调控机制,为Th17细胞相关疾病的治疗提供了新

J Exp Med:论文!清华大学董晨课题组发现自身免疫病调控新机理

2018年 1月29 日,清华大学免疫学研究所董晨课题组在国际著名学术期刊《Journal of Experimental Medicine》在线发表题为“Deficiency in T follicular regulatory cells promotes autoimmunity”的研究论文,报道了Tfr细胞控制自身免疫性疾病的关键作用。